| Project/Area Number |
23590532
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Bacteriology (including Mycology)
|
|---|
| Research Institution | Clinical Research Center, National Hospital Organization, Kinki-Chuo Chest Medical Center |
|---|
Principal Investigator |
OKADA Masaji 独立行政法人国立病院機構(近畿中央胸部疾患センター臨床研究センター), その他部局等, その他 (40160684)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SUZUKI Katsuhiro 国立病院機構近畿中央胸部疾患センター, 統括診療部長 (00206468)
TSUYUGUCHI Kazunari 国立病院機構近畿中央胸部疾患センター, 臨床研究センター, 感染症研究部長 (00359308)
YOSHIDA Shigeto 金沢大学, 医薬保健研究域薬学系, 教授 (10296121)
OHARA Naoya 岡山大学, 大学院医歯薬学総合研究科, 教授 (70223930)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2011: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Keywords | 結核ワクチン / Granulysin / granulysinレセプター / キラーT細胞分化 / 結核予防ワクチン / 結核治療ワクチン / ポジティブフィードバック / レセプター単離 / HSP65タンパク |
|---|
| Research Abstract |
Cytotoxic T cells against M. tuberculosis are one of most important immune cells for the protection of tuberculosis infection in human.
(1)It was demonstrated first that HSP65 DNA+IL-12 DNA vaccine (HSP65 vaccine) and 15K Granulysin vaccine exerted the activity of cytotoxic T cell differentiation factor in the present study. (2)Therefore, the presence of the receptor for granulysin was strongly suggested. We are now isolating the granulysin receptor. (3)We found granulysin-granulysin positive feedback loop. Granulysin was produced from CTL, and granulysin act on the differentiation of CTL. (4)HSP65 vaccine and Granulysin vaccine exerted synergistic therapeutic efficacy against TB infection in mice, and showed the synergistic differentiation of CTL.
|
